Friday, July 10, 2026

Patent intelligence · US

US 10285964

Fatty-acid based particles

granted A61KA61K31/00A61K31/20A61K31/4353
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 13
Applicant portfolio 37
Patent details — US 10285964
Jurisdiction
US
Status
granted
Grant date
May 14, 2019
Expiration
May 9, 2039
Claims
11
CPC classes
A61K, A61K31/00, A61K31/20, A61K31/4353
View on Google Patents ↗

Quick answer

US 10285964 (Fatty-acid based particles) is held by ATRIUM MEDICAL CORPORATION. Status: granted. Granted May 14, 2019. Expires May 9, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
11
CPC classes
A61K, A61K31/00, A61K31/20, A61K31/4353, A61K31/436, A61K31/445

More from ATRIUM MEDICAL CORPORATION

Related pharmaceutical patents in our USPTO index.

  1. US 11793912

    Cross-linked fatty acid-based biomaterials

    ATRIUM MEDICAL CORPORATION · Expires Oct 19, 2043

    granted
  2. US 11166929

    Fatty-acid based particles

    ATRIUM MEDICAL CORPORATION · Expires Nov 4, 2041

    granted
  3. US 11097035

    Compositions and methods for altering the rate of hydrolysis of cured oil-based materials

    ATRIUM MEDICAL CORPORATION · Expires Aug 19, 2041

    granted
  4. US 11083823

    Tissue-separating fatty acid adhesion barrier

    ATRIUM MEDICAL CORPORATION · Expires Aug 5, 2041

    granted
  5. US 10888617

    Cured oil-hydrogel biomaterial compositions for controlled drug delivery

    ATRIUM MEDICAL CORPORATION · Expires Jan 7, 2041

    granted
  6. US 10869902

    Cured gel and method of making

    ATRIUM MEDICAL CORPORATION · Expires Dec 17, 2040

    granted
  7. US 10864304

    Anti-infective antimicrobial-containing biomaterials

    ATRIUM MEDICAL CORPORATION · Expires Dec 10, 2040

    granted
  8. US 10814043

    Cross-linked fatty acid-based biomaterials

    ATRIUM MEDICAL CORPORATION · Expires Oct 22, 2040

    granted

Frequently asked questions

What is US patent 10285964?

US 10285964 (Fatty-acid based particles) is held by ATRIUM MEDICAL CORPORATION. Status: granted. Granted May 14, 2019. Expires May 9, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10285964?

ATRIUM MEDICAL CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 37 pharmaceutical patents for this assignee.

When does US 10285964 expire?

Our index shows an expiration date of May 9, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.